Rigel Pharmaceuticals (RIGL) Q4 2025 earnings summary

Executive summary

• Achieved record total revenues of $294.3 million and net product sales of $232 million in 2025, up 60% year-over-year, driven by strong demand and portfolio expansion.

• Transitioned from a single-product to a three-product commercial portfolio, with TAVALISSE, REZLIDHIA, and GAVRETO approved for four indications and expanded global reach.

• Maintained profitability since Q3 2024, with net income of $367 million for 2025, aided by a $245.9 million non-cash deferred tax benefit.

• Advanced clinical pipeline, notably R289 for lower-risk MDS, with Fast Track and Orphan Drug designations and promising early clinical results.

• Strategic focus on commercial growth, late-stage in-licensing, disciplined capital allocation, and sustained value creation.

Financial highlights

• Full-year 2025 revenues were $294.3 million, including $232 million in net product sales and $62 million in contract revenues.

• Q4 2025 net product sales were $65.4 million, up 41% year-over-year; total Q4 revenue was $69.8 million.

• Net income for 2025 was $367 million, up from $17.5 million in 2024, benefiting from a $245.9 million non-cash deferred income tax benefit.

• Cash and short-term investments at year-end were $155 million, up from $77.3 million in 2024.

• Total costs and expenses for 2025 were $168.8 million, mainly due to increased R&D and personnel costs.

Outlook and guidance

• 2026 revenue guidance: $275–$290 million, with $255–$265 million in net product sales and $20–$25 million in contract revenues.

• Expects continued double-digit sales growth in 2026, though not at 2025's exceptional rate due to one-time effects.

• Anticipates positive net income in 2026 while funding ongoing and new clinical programs.

• Plans to complete R289 Phase 1b dose expansion and select Phase 2 dose in 2H 2026, with updated data by year-end.